FDA — authorised 17 December 2021
- Application: BLA761224
- Marketing authorisation holder: ASTRAZENECA AB
- Local brand name: TEZSPIRE
- Indication: SOLUTION — SUBCUTANEOUS
- Status: approved
🇺🇸 Tezspire in United States
FDA authorised Tezspire on 17 December 2021
Marketing authorisations
FDA
- Status: approved
Tezspire in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Respiratory approved in United States
Frequently asked questions
Is Tezspire approved in United States?
Yes. FDA authorised it on 17 December 2021; FDA has authorised it.
Who is the marketing authorisation holder for Tezspire in United States?
ASTRAZENECA AB holds the US marketing authorisation.